Log in

NYSEAMERICAN:ATNM - Actinium Pharmaceuticals Stock Price, Forecast & News

$0.27
-0.01 (-3.52 %)
(As of 01/17/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.27
Now: $0.27▼
$0.28
50-Day Range N/A
52-Week Range
$0.19
Now: $0.27▼
$0.71
Volume3.22 million shs
Average Volume4.81 million shs
Market Capitalization$44.98 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:ATNM
Previous SymbolAMEX:ATNM
CUSIPN/A
CIKN/A
Webhttp://www.actiniumpharmaceuticals.com/
Phone+1-646-6773875

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees30
Outstanding Shares164,171,000
Market Cap$44.98 million
Next Earnings Date3/17/2020 (Estimated)
OptionableOptionable

Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

AMEX:ATNM Rates by TradingView

Stock Trades Or Predictions (Ad)


Want to know which stocks should be on your radar this week? Every Sunday we send out the 3 Stock Trades that we predict will be big winners for the week ahead.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) released its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). View Actinium Pharmaceuticals' Earnings History.

When is Actinium Pharmaceuticals' next earnings date?

Actinium Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Actinium Pharmaceuticals.

What price target have analysts set for ATNM?

3 analysts have issued twelve-month price objectives for Actinium Pharmaceuticals' shares. Their forecasts range from $1.50 to $5.00. On average, they anticipate Actinium Pharmaceuticals' stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 1,086.1% from the stock's current price. View Analyst Price Targets for Actinium Pharmaceuticals.

What is the consensus analysts' recommendation for Actinium Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals.

What are Wall Street analysts saying about Actinium Pharmaceuticals stock?

Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (11/20/2019)
  • 2. Maxim Group analysts commented, "Actinium reported 4Q18 and FY18 with a net loss of ($6.4M) and ($23.7M), respectively. The company ended the year with $13.6M in cash on the balance sheet (not including $2.5M warrant exercises). The company also has a $30M ATM in place. Combined, the company should have sufficient runway to get the P3 data for Iomab in 1H20." (3/20/2019)

Has Actinium Pharmaceuticals been receiving favorable news coverage?

News stories about ATNM stock have trended very positive on Saturday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Actinium Pharmaceuticals earned a news sentiment score of 3.4 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Actinium Pharmaceuticals.

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,500,000 shares, an increase of 22.8% from the December 15th total of 2,850,000 shares. Based on an average daily volume of 2,620,000 shares, the short-interest ratio is presently 1.3 days. Approximately 2.2% of the shares of the stock are short sold. View Actinium Pharmaceuticals' Current Options Chain.

Who are some of Actinium Pharmaceuticals' key competitors?

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Opko Health (OPK), TransEnterix (TRXC), Tandem Diabetes Care (TNDM), Sorrento Therapeutics (SRNE), Cancer Genetics (CGIX), AK Steel (AKS) and Align Technology (ALGN).

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the folowing people:
  • Mr. Sandesh C. Seth, Chairman & CEO (Age 55)
  • Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)
  • Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Mark S. Berger, Chief Medical Officer (Age 64)
  • Mr. Anil Kapur, Chief Commercial Officer (Age 50)

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $0.27.

How big of a company is Actinium Pharmaceuticals?

Actinium Pharmaceuticals has a market capitalization of $44.98 million. Actinium Pharmaceuticals employs 30 workers across the globe.View Additional Information About Actinium Pharmaceuticals.

What is Actinium Pharmaceuticals' official website?

The official website for Actinium Pharmaceuticals is http://www.actiniumpharmaceuticals.com/.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.


MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Featured Article: How to calculate compound interest
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel